127 related articles for article (PubMed ID: 20385615)
1. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.
Eder L; Chandran V; Schentag CT; Shen H; Cook RJ; Gladman DD
Rheumatology (Oxford); 2010 Jul; 49(7):1361-6. PubMed ID: 20385615
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
3. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
Glintborg B; Østergaard M; Dreyer L; Krogh NS; Tarp U; Hansen MS; Rifbjerg-Madsen S; Lorenzen T; Hetland ML
Arthritis Rheum; 2011 Feb; 63(2):382-90. PubMed ID: 21279995
[TBL] [Abstract][Full Text] [Related]
4. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
5. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
6. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
[TBL] [Abstract][Full Text] [Related]
8. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
[TBL] [Abstract][Full Text] [Related]
9. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
10. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
[TBL] [Abstract][Full Text] [Related]
12. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
13. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
14. Minimal important difference and responsiveness to change of the SF-36 in patients with psoriatic arthritis receiving tumor necrosis factor-α blockers.
Leung YY; Zhu TY; Tam LS; Kun EW; Li EK
J Rheumatol; 2011 Sep; 38(9):2077-9. PubMed ID: 21885524
[No Abstract] [Full Text] [Related]
15. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
[TBL] [Abstract][Full Text] [Related]
16. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
17. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
18. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Gladman DD; Ziouzina O; Thavaneswaran A; Chandran V
J Rheumatol; 2013 Aug; 40(8):1357-9. PubMed ID: 23818708
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study.
Tam LS; Li EK; Shang Q; Tomlinson B; Li M; Leung YY; Kuan WP; Kwok LW; Li TK; Zhu Y; Kun EW; Yip G; Yu CM
Ann Rheum Dis; 2011 Apr; 70(4):705-6. PubMed ID: 20647274
[No Abstract] [Full Text] [Related]
20. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
